POINT Biopharma Global Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $13.90 |
| Prev. Close | $13.81 |
| EPS | 1.10 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 14, 2023 |
| Dividend Yield % | - |
| Market Cap | $1.45B |
| PE Ratio | 12.41 |
| low | high | |
|---|---|---|
| Day Range | 13.45 | 13.91 |
| 52 Week Range | 6.39 | 13.91 |
| Ratios | |
|---|---|
| P/B Ratio | 3.47 |
| Revenue | $243.69M |
| Operating M. % | -1,061.87% |
| Earnings | $96.55M |
| Earnings Growth % | - |
| EBITDA Margin % | 45.29% |
| ROE % | 26.33% |
| EPS | 1.10 |
Score Breakdown
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| PNT | Market | |
|---|---|---|
| Value | 31 | 42 |
| Quality | 54 | 46 |
| Ownership | 73 | 39 |
| Growth | 73 | 44 |
| Dividends | - | 32 |
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About POINT Biopharma Global Inc. (PNT)
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Joe A. McCann Ph.D.
- Headquarters
- Indianapolis
- Employees
- 129
Keep an eye on POINT Biopharma Global Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.